Fluent stock surges after securing new $30 million financing facility

Investing.com -- Morgan Stanley has identified three standout performers in the life science tool sector, with a particular focus on precision oncology companies that continue to outpace the broader market.

The precision oncology vertical has been a bright spot in the life sciences space, with significant stock price appreciation since early 2023. According to Morgan Stanley, these companies are trading at premium valuations that appear sustainable based on market penetration opportunities and potential ASP (average selling price) upside across minimal residual disease, therapy selection, and screening applications.

Get more stock picks by Wall Street analysts by upgrading to - get 60% off today

Here’s a look at the top-ranked stocks in this sector:

Guardant Health - Morgan Stanley has initiated coverage with an Overweight rating and a $130 price target. The firm’s analysis of GH’s screening P&L validates management’s longer-term targets, with the company expected to achieve operating profitability by 2028. While the screening business will likely continue operating at a loss as annual revenues approach $600 million, the non-screening segments are projected to scale up to high-teens operating margins by 2029. The G360 product continues to gain momentum, and the benefits of GH’s Smart platform are expected to become increasingly evident as test volumes scale.

In recent news, Guardant Health reported third-quarter revenues that surpassed consensus estimates by 13%, prompting Raymond James to raise its price target on the company. Guardant also announced the expansion of its Guardant Reveal blood test to monitor therapy response in patients with advanced solid tumors.

Natera - Morgan Stanley assumes coverage with an Overweight rating and a $265 price target. Despite Natera’s NIPT (non-invasive prenatal testing) product Panorama being on the market since 2013, the firm sees healthy upside risk to consensus estimates for 2026. This optimism persists even though US penetration now sits in the low 60% range, thanks to what the analysts describe as a "solid data moat." The Signatera product is expected to maintain its leadership position in minimal residual disease testing, with management’s framework for 2026 leaving room for potential upside.

Natera recently posted third-quarter revenue that beat expectations by over 15%, though its earnings per share missed forecasts. Following the results, several investment firms, including Stephens and TD Cowen, increased their price targets for the company.

Tempus AI - Morgan Stanley initiates coverage with an Overweight rating and an $85 price target. Beyond genomics, the firm conducted a deep dive into TEM’s Data & Services business, an area where they believe some investors struggle to validate management’s growth outlook. After breaking out contract values from major customer agreements and speaking with two large pharma customers, Morgan Stanley received "highly complementary feedback" on the platform and clear intentions from customers to increase their data utilization going forward.

Tempus AI announced third-quarter results that exceeded analyst forecasts for both revenue and earnings per share. The company also entered into a new multi-year research partnership with the Institute for Follicular Lymphoma Innovation.

Morgan Stanley’s research includes a survey of 80 US oncology specialists, which points to strong volume growth into 2026 and provides insights on expected market share shifts among competitors in this rapidly evolving sector.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Investing.com -- The Trump administration plans to unveil new fuel efficiency standards for automobiles on Wednesday, according to Bloomberg News, which cited people familiar with the matter.

The announcement, expected to take place at the White House, aims to revise existing requirements that the administration has criticized for increasing new car prices.

Top automotive industry leaders are planning to attend the event, including the chief executive officer of Stellantis NV, the parent company of Jeep, along with senior executives from General Motors Co. and Ford Motor Co.

The specific details of the proposed fuel efficiency requirements have not yet been disclosed.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Investing.com -- AeroVironment Inc (NASDAQ:AVAV) stock gained 2.7% on Tuesday after the defense technology company announced new additions to its AV_Halo unified mission software platform.

The company unveiled AV_Halo CORTEX, an AI-driven intelligence fusion and analysis environment, and AV_Halo MENTOR, a warfighter readiness suite that provides immersive virtual and augmented reality training. These new products extend the capabilities of the AV_Halo platform that was initially launched in September.

"In today’s rapidly evolving operational environment, the advantage goes to those who can understand faster and prepare smarter," said Wahid Nawabi, AV Chairman, President, and Chief Executive Officer in the announcement.

AV_Halo CORTEX leverages the company’s Scraawl technology to collect and analyze millions of data points from open sources, including news content, social media, imagery, and sensor feeds. The system uses AI to accelerate intelligence gathering and features a proprietary geolocation engine that works using only visual cues.

Meanwhile, AV_Halo MENTOR offers virtual reality training for operators of various weapons systems, including Stinger and Javelin. The system creates immersive 360-degree environments using real-world data and supports both individual and team-based training scenarios.

The company indicated it will continue expanding the AV_Halo platform with additional capabilities, including autonomous mission agents and enhanced airspace deconfliction tools. The platform follows the Modular Open Systems Approach mandated by the U.S. Department of War to improve interoperability in defense systems.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Investing.com – Poland stocks were lower after the close on Tuesday, as losses in the Energy, Banking and Oil & Gas sectors led shares lower.

At the close in Warsaw, the WIG30 fell 1.21%.

The best performers of the session on the WIG30 were Asseco Poland SA (WA:ACPP), which rose 3.89% or 7.60 points to trade at 203.00 at the close. Meanwhile, Text SA (WA:TXTP) added 3.77% or 1.52 points to end at 41.82 and Rainbow Tours SA (WA:RBW) was up 0.67% or 0.90 points to 134.80 in late trade.

The worst performers of the session were Santander Bank Polska SA (WA:SPL1), which fell 5.84% or 29.90 points to trade at 481.70 at the close. PGE Polska Grupa Energetyczna SA (WA:PGE) declined 4.65% or 0.44 points to end at 8.99 and Allegro (WA:ALEP) was down 3.11% or 1.00 points to 31.33.

Falling stocks outnumbered advancing ones on the Warsaw Stock Exchange by 318 to 223 and 99 ended unchanged.

Crude oil for January delivery was down 0.59% or 0.35 to $58.97 a barrel. Elsewhere in commodities trading, Brent oil for delivery in February fell 0.55% or 0.35 to hit $62.82 a barrel, while the February Gold Futures contract fell 1.35% or 57.55 to trade at $4,217.25 a troy ounce.

EUR/PLN was up 0.28% to 4.24, while USD/PLN rose 0.30% to 3.65.

The US Dollar Index Futures was up 0.06% at 99.43.

Investing.com -- BioNexus Gene Lab Corp. (NASDAQ:BGLC) stock fell 3.8% Tuesday after the precision oncology diagnostics provider announced it has entered into a $500 million Equity Purchase Agreement with ARC Group International Ltd.

The 36-month facility allows BioNexus to issue and sell registered shares of its common stock to ARC at its sole discretion. As compensation for ARC’s commitment, BioNexus issued 175,000 shares of common stock as a one-time fee, priced at $4.32, the closing price on November 26.

The agreement prohibits ARC from owning more than 9.99% of BioNexus’s outstanding shares at any time and restricts the investment bank from short-selling or hedging the company’s securities. BioNexus will file a registration statement for the resale of shares issued under the facility, with no shares to be sold prior to registration.

This new facility complements BioNexus’s previously announced $20 million At-The-Market program, providing additional financial flexibility as the company pursues strategic initiatives including the commercialization of its VitaGuard minimal residual disease platform in Southeast Asia.

"This commitment from ARC strengthens our capital position at a pivotal time for BGLC," said Sam Tan, Chief Executive Officer of BioNexus Gene Lab Corp. "We intend to draw from this resource selectively and responsibly as we advance our diagnostics, CDMO, and therapeutic commercialization programs."

The company is expanding its operations across Southeast Asia and working to add contract development and manufacturing organization services to its regional business portfolio.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.